Xenetic Biosciences Inc (NASDAQ:XBIO) was the recipient of a significant growth in short interest in the month of June. As of June 30th, there was short interest totalling 83,900 shares, a growth of 67.5% from the May 30th total of 50,100 shares. Currently, 2.5% of the shares of the company are short sold. Based on an average daily trading volume, of 51,200 shares, the short-interest ratio is presently 1.6 days.
NASDAQ:XBIO opened at $12.69 on Friday. The company has a 50 day simple moving average of $4.35. Xenetic Biosciences has a 12-month low of $6.12 and a 12-month high of $61.80.
Xenetic Biosciences (NASDAQ:XBIO) last released its quarterly earnings data on Friday, May 10th. The company reported ($0.54) earnings per share (EPS) for the quarter.
Xenetic Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, research, and development of next-generation biologic drugs and novel orphan oncology therapeutics. The company's lead investigational product candidate is oncology therapeutic XBIO-101 (sodium cridanimod) for the treatment of progesterone resistant endometrial cancer.
Featured Story: What is a Call Option?
Receive News & Ratings for Xenetic Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenetic Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.